Willfulness, Reissue and Reexam Prof Merges Nov. 18, 2010.

Slides:



Advertisements
Similar presentations
By David W. Hill AIPLA Immediate Past President Partner Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Overview of the America Invents Act.
Advertisements

© Kolisch Hartwell 2013 All Rights Reserved, Page 1 America Invents Act (AIA) Implementation in 2012 Peter D. Sabido Intellectual Property Attorney Kolisch.
Joint Meeting of PIPLA and NJIPLA February 7, 2012 Kenneth N. Nigon RatnerPrestia 1.
Seagate - Willfulness Prof Merges April 22, 2008.
Grand Jury Practice and Indictments
G & B Seminar 2006 Duty of Disclosure for Enforceable/Valid U.S. Patents Daniel Moon.
Greg Gardella Patent Reexamination: Effective Strategy for Litigating Infringement Claims Best Practices for Pursuing and Defending Parallel Proceedings.
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
Post-Issuance Proceedings Under the AIA Thomas F. Cotter Briggs and Morgan Professor of Law University of Minnesota Law School.
Administrative Trials
America Invents Act (AIA) Changes in Patent Law That Impact Companies May Mowzoon: Mowzoon Law Office, PLLC 1.
Appeal Practice Before Board of Patent Appeals and Interferences
Filing Compliant Reexam Requests Andy Kashnikow SPE, Central Reexamination Unit Andy Kashnikow SPE, Central Reexamination Unit June, 2010.
AMERICA INVENTS ACT A Look Into The Future
Announcements l Beginning Friday at 10:50 a.m., you and your moot court partner may sign up as Appellees or Appellants. l The sign-up sheet will be posted.
Greg H. Gardella Ex Parte and Inter Partes Reexamination Tactics AIPLA 2010 Winter Institute.
Go Back, Jack, Do it Again: Reissue and Reexam Patent Law
Patent Defenses and Remedies Intro to IP – Prof Merges
Willfulness, Reissue and Reexam Prof Merges Nov. 17, 2011.
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
1 REISSUE OVERVIEW 35 USC Filing Requirements 2. Oaths or Declarations 3. Grounds for Filing 4. Consent 5. Limitations 6. Recapture.
1 BROADENING REISSUES Bennett Celsa TC1600 Quality Assurance Specialist.
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
The U.S. Patent System is Changing – A Summary of the New Patent Reform Law.
AIA Strategies.
IP Gespräche 2009 Frankfurt ● Karlsruhe ● Basel ● Zürich Strategic Uses of U.S. Reexamination Proceedings – Strengthen Your Market Position and Avoid U.S.
Information Disclosure Statements
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
February 19, Recent Changes and Developments in USPTO Practice Prepared by: Office of Patent Legal Administration (OPLA) Robert J. Spar, DirectorJoni.
Anthony Venturino MILANO 10 February 2012 SELECTED PROVISIONS OF THE LEAHY Smith AMERICA INVENTS ACT OF 2011 AIPPI - AIPLA 1 © AIPLA
Remy Yucel Director, CRU (571) Central Reexamination Unit and the AIA.
1 EXAMINER’S REASONS FOR ALLOWANCE Samson Helfgott Director of Patents KMZ Rosenman New York, N.Y. January, To Respond, or not to Respond?
Impact of US AIA: What Really Changed? 1 © AIPLA 2015.
1 Patent Law in the Age of IoT The Landscape Has Shifted. Are You Prepared? 1 Jeffrey A. Miller, Esq.
Discovery III Expert Witness Disclosure And Discovery Motions & Sanctions.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Post-Grant & Inter Partes Review Procedures Presented to AIPPI, Italy February 10, 2012 By Joerg-Uwe Szipl Griffin & Szipl, P.C.
1 Rules of Practice Before the BPAI in Ex Parte Appeals 73 Fed. Reg (June 10, 2008) Effective December 10, Fed. Reg (June 10, 2008)
1 1 AIPLA Firm Logo American Intellectual Property Law Association Update on AIA Implementation Especially post grant processes Alan J. Kasper AIPLA/JPO.
Mon. Nov. 26. Work Product “Privilege” A witness, X, who is friendly to the D was interviewed by P’s attorney and a statement was drawn up Is there any.
Reexamination at the USPTO Robert A. Clarke Deputy Director Office of Patent Legal Administration USPTO Robert A. Clarke Deputy Director Office of Patent.
1 1 AIPLA Firm Logo American Intellectual Property Law Association The Presumption of Patent Validity in the U.S. Tom Engellenner AIPLA Presentation to.
New Ex Parte Appeal Rules Patent and Trademark Practice Group Meeting January 26, 2012.
3 rd Party Participation Bennett Celsa TC 1600 QAS.
© COPYRIGHT DICKSTEIN SHAPIRO LLP. ALL RIGHTS RESERVED. Post Grant Proceedings Before the USPTO and Litigation Strategies Under the AIA Panelists:David.
America Invents Act  Date of enactment: 9/16/11  First-to-file provisions effective 18 months after enactment – March 16, 2013  Applications filed on.
Patent Defenses and Remedies Intro to IP – Prof Merges
Biotechnology Chemical Pharmaceutical Customer Partnership
Derivation Proceedings Gene Quinn Patent Attorney IPWatchdog.com March 27 th, 2012.
Prosecution Group Luncheon September, America Invents Act Passed House and Senate (HR 1249) Presidential Signature expected Friday Most provisions.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association THE STATUS OF INDUCEMENT Japan Intellectual Property Association Tokyo Joseph A. Calvaruso.
Overview of the FTC’s 2003 Proposed Reforms to U.S. Patent Law David W. Hill.
1 Eleventh National HIPAA Summit The New HIPAA Enforcement Rule Gerald “Jud” E. DeLoss, Esq. General Counsel Fairmont Orthopedics & Sports Medicine, P.A.
Willfulness, Reissue and Reexam Prof Merges Nov. 15, 2012.
1 1 AIPLA 1 1 American Intellectual Property Law Association USPTO Post-Grant Procedures and Effective Use of Reissue AIPLA IP Practice in Japan Committee.
PTAB Litigation 2016 Part 6 – Patent Owner Response 1.
The Impact of Patent Reform on Independent Inventors and Start-up Companies Mark Nowotarski (Patent Agent)
HOT TOPICS IN PATENT LITIGATION ABA – IP Section, April 9, 2011 Committee 601 – Trial and Appellate Rules & Procedures Moderator: David Marcus Speakers:
Presentation at Biotechnology/ Chemical/Pharmaceutical Customer Partnership Program Partnership Program March 15, 2005 POST-GRANT REVIEW: A COMPARISON.
1 TOPIC III - PATENT INVALIDATION PROCEDURES EU-CHINA WORKSHOP ON THE CHINESE PATENT LAW HARBIN, SEPTEMBER 2008 Dr. Gillian Davies.
Recent Developments in Obtaining and Enforcing Intellectual Property Rights in Nanocomposites Michael P. Dilworth February 28, 2012.
Open Meetings, Public Records, Conflicts of Interest, EMC Bylaws, and Penalty Remissions* Jennie Wilhelm Hauser Special Deputy Attorney General Presentation.
The Applicability of Patent-Agent Privilege After In re Queen’s University at Kingston Presented by Rachel Perry © 2016 Workman Nydegger.
Inter Partes Review and District Court
Enhanced Damages for Patent Infringement: Halo v. Pulse
America Invents Act: Litigation Related Provisions
Biotechnology Chemical Pharmaceutical Customer Partnership
PTAB Bar Association Conference—March 2, 2017
James Toupin POST-GRANT REVIEW: A COMPARISON OF USPTO
Presentation transcript:

Willfulness, Reissue and Reexam Prof Merges Nov. 18, 2010

Agenda Willful infringement Reissue Reexamination

Willful Patent Infringement Development of the doctrine Court “may increase damages up to 3x” Knowledge  proof  opinion letters

1. Should a party's assertion of the advice of counsel defense to willful infringement extend waiver of the attorney-client privilege to communications with that party's trial counsel? See In re EchoStar Commc'ns Corp., 448 F.3d 1294 (Fed.Cir.2006). 2. What is the effect of any such waiver on work- product immunity? 3. Given the impact of the statutory duty of care standard announced in Underwater Devices, Inc. v. Morrison-Knudsen Co., 717 F.2d 1380 (Fed.Cir.1983), on the issue of waiver of attorney-client privilege, should this court reconsider the decision in Underwater Devices and the duty of care standard itself?

35 USC 284 When the damages are not found by a jury, the court shall assess them. In either event the court may increase the damages up to three times the amount found or assessed. Increased damages under this paragraph shall not apply to provisional rights under section 154(d) of this title. The court may receive expert testimony as an aid to the determination of damages or of what royalty would be reasonable under the circumstances.

“Traditional” Federal Circuit rule “Where... a potential infringer has actual notice of another's patent rights, he has an affirmative duty to exercise due care to determine whether or not he is infringing. Such an affirmative duty includes, inter alia, the duty to seek and obtain competent legal advice from counsel before the initiation of any possible infringing activity.” – Underwater Devices

Optimized Trajectories for Motion Control: Convolve, Inc.

Convolve: curl, wind, or twist together Applied to functions: a mathematical “intertwining” of two separate functions

The duty of due care standard has led to punitive damages based on nothing more than a negligent failure to proceed with “due care.” See, e.g., Stryker Corp. v. Davol, Inc., 234 F.3d 1252, 1259 (Fed. Cir. 2000) (declining to overturn jury finding of willful infringement when evidence indicated that reliance on advice of counsel was “unreasonable”)

But the duty of due care standard shifts to the defendant the burden of demonstrating that it has acted with sufficient care to forestall a finding of willful infringement. See Knorr-Bremse Systeme Fuer Nutzfahrzeuge GmBH v. Dana Corp., 383 F.3d 1337, 1349 (Fed. Cir. 2004) (en banc) (Dyk, J.) (this “effectively shifts the burden of proof on the issue of willfulness from the patentee to the infringer”).

Seagate opinion Over the years, we had held that an accused infringer's failure to produce advice from counsel “would warrant the conclusion that it either obtained no advice of counsel or did so and was advised that its [activities] would be an infringement of valid U.S. Patents.” Knorr- Bremse, 383 F.3d at 1343 Supp. P. 132

Supp. P. 133 Just recently, the Supreme Court addressed the meaning of willfulness as a statutory condition of civil liability for punitive damages. Safeco Ins. Co. of Am. v. Burr, --- U.S. ----, 127 S.Ct. 2201, 167 L.Ed.2d 1045 (2007) [T]he Court concluded that the “standard civil usage” of “willful” includes reckless behavior. Id. at 2209

In contrast, the duty of care announced in Underwater Devices sets a lower threshold for willful infringement that is more akin to negligence. This standard fails to comport with the general understanding of willfulness in the civil context, Richland Shoe Co., 486 U.S. at 133, 108 S.Ct (“The word ‘willful’... is generally understood to refer to conduct that is not merely negligent.”), and it allows for punitive damages in a manner inconsistent with Supreme Court precedent

Supp. P. 134 Accordingly, we overrule the standard set out in Underwater Devices and hold that proof of willful infringement permitting enhanced damages requires at least a showing of objective recklessness. Because we abandon the affirmative duty of due care, we also reemphasize that there is no affirmative obligation to obtain opinion of counsel.

When opinions are sought, NO waiver of attorney-client privilege with respect to trial counsel Which removes a large disincentive to seek opinion letters and to “pre-clear” patent issues generally

Reissues and Reexamination Both are post-issuance administrative proceedings – PTO involvement with patents does NOT end with issuance Both have specific procedures and requirements; and strategic uses

Reissues Background Mentor v. Coloplast

251. Reissue of Defective Patents. Whenever any patent is, through error without any deceptive intention, deemed wholly or partly inoperative or invalid, by reason of a defective specification or drawing, or by reason of the patentee claiming more or less than he had a right to claim in the patent, the Commissioner shall, on the surrender of such patent…, reissue the patent for the invention disclosed in the original patent, and in accordance with a new and amended application, for the unexpired part of the term of the original patent. No new matter shall be introduced into the application for reissue.

Elements Whenever any patent is, [1] through error without any deceptive intention, deemed [2] wholly or partly inoperative or invalid, by reason of a [3] defective specification or drawing, or by reason of the patentee claiming more or less than he had a right to claim in the patent, the Commissioner shall, on the surrender of such patent

Key Provision “through error without any deceptive intention” – Error: mistake, inadvertence – Without deceptive intention No plan to broaden or recapture... Not the result of a strategic decision during prosecution

The Commissioner may issue several reissued patents for distinct and separate parts of the thing patented, upon demand of the applicant, and upon payment of the required fee for a reissue for each of such reissued patents. The provisions of this title relating to applications for patent shall be applicable to applications for reissue of a patent, except that application for reissue may be made and sworn to by the assignee of the entire interest if the application does not seek to enlarge the scope of the claims of the original patent.

251. Reissue of Defective Patents, cont’d No reissued patent shall be granted enlarging the scope of the claims of the original patent unless applied for within two years from the grant of the original patent.

Broadening Reissues No reissued patent shall be granted enlarging the scope of the claims of the original patent unless applied for within two years from the grant of the original patent. “2 Year Rule”

The two-year period is not based on the priority date but on the issue date. 35 U.S.C. § 251; M.P.E.P. ¶ Accordingly, a broadening reissue may be filed on a continuation or divisional application more than two years after the issue date of the parent patent so long at it is filed within two years of the issue date of the continuation patent.

A reissued patent shall not abridge or affect the right of any person who …, prior to the grant of a reissue, made, purchased, offered to sell, or used within the United States, or imported into the United States, anything patented by the reissued patent, to continue the use of, to offer to sell, … unless the making, using, offering for sale, or selling of such thing infringes a valid claim of the reissued patent which was in the original patent. Intervening rights – section 252

The court before which such matter is in question may provide for the continued manufacture, use, offer for sale, or sale of the thing made, purchased, offered for sale, used, or imported as specified, or for the manufacture, use, offer for sale, or sale in the United States of which substantial preparation was made before the grant of the reissue, and the court may also provide for the continued practice of any process patented by the reissue that is practiced, or for the practice of which substantial preparation was made, before the grant of the reissue, to the extent and under such terms as the court deems equitable for the protection of investments made or business commenced before the grant of the reissue.

Reissue Requirements (1) “Error in the patent” and (2) “Error in Conduct”

Error in the Patent -- Claiming too much (after- discovered prior art) -- Not claiming enough (after- discovered competitor product)

Some Defects are too Big! Complete anticipation Insufficient disclosure

Rules cont’d Error in conduct – Reissue cures only some types of conduct Cannot cure Inequitable conduct, e.g.

Mentor v. Coloplast Why did Mentor seek a reissue? How did this relate to its litigation strategy?

“An attorney’s failure to appreciate the full scope of the invention” is not an uncommon defect in claiming an invention. In re Wilder, 736 F.2d 1516, 222 U.S.P.Q. 369 (Fed. Cir. 1984), cert. denied, 469 U.S (1985).

Mentor v. Coloplast Recapture rule – Only applies to broadened reissue claims Cannot recapture subject matter surrendered in original prosecution Nuanced application: claims broader in some ways than original, narrower than in original

Mentor’s initial claims, which did not require the transfer of the adhesive from the outer to the inner catheter surface, were rejected by the examiner. Mentor then added the adhesive transfer limitation and argued that the amended claims should be allowed because “none of the references relied upon actually showed the transfer of adhesive from the outer surface to the inner surface as the sheath is rolled up and then unrolled.” The amended claims were allowed. Mentor then sought and obtained the reissue patent containing claims 6-9.

p Reissue claim 6, which does not include the adhesive transfer limitation, impermissibly recaptures what Mentor deliberately surrendered in the original prosecution. Specifically, the reissue claims do not contain the limitation that, during rolling and unrolling, the adhesive be transferred from the outer to the inner surface of the catheter.

Reissue vs. Reexam Reissue: available to fix patent for any cause that makes it “inoperative or invalid”; can be broadening (2 yr rule) Only the patentee may request reissue: “upon surrender or the patent...” Can be withdrawn by patentee at any time

Reexam Can be requested by anyone The types of prior art which may be considered in a reexamination proceeding are limited to patents and printed publications. 35 U.S.C. § 301; 37 C.F.R. § 1.552

Traditional (Ex Parte) Reexams Third party participation in a traditional reexamination is limited. If a third party requests reexamination, the patent owner is notified and provided an opportunity to submit a statement in opposition to an order for reexamination. 35 U.S.C. § 302; 37 C.F.R. §§ 1.510(b)(5), 1.530(b).

If the patent owner submits a statement, the requestor is given an opportunity to reply. 37 C.F.R. § Otherwise, a non-patentee requestor's participation ends with the request for reexamination. However, the patentee is required to serve on the requestor a copy of all papers filed with the Patent Office. 37 C.F.R. § 1.550(e).

35 U.S.C. 301 Citation of prior art. Any person at any time may cite to the Office in writing prior art consisting of patents or printed publications which that person believes to have a bearing on the patentability of any claim of a particular patent. If the person explains in writing the pertinency and manner of applying such prior art to at least one claim of the patent, the citation of such prior art and the explanation thereof will become a part of the official file of the patent.

Section 302.Request for Reexamination Any person at any time may file a request for reexamination by the Office of any claim of a patent on the basis of any prior art cited under the provisions of Section 301 of this title. … The request must set forth the pertinency and manner applying cited prior art to every claim for which reexamination is requested. Unless the requesting person is the owner of the patent, the Commissioner promptly will send a copy of the request to the owner of record of the patent.

What is required? 303 (a): Within three months following the filing of a request for reexamination under the provisions of section 302 of this title, the Director will determine whether a substantial new question of patentability affecting any claim of the patent concerned is raised by the request, with or without consideration of other patents or printed publications

Reexam result Commissioner may issue “a certificate canceling any claim of the patent finally determined to be unpatentable, confirming any claim of the patent determined to be patentable, and incorporating in the patent any proposed amended or new claim determined to be patentable.” 35 U.S.C. § 307(a).

BUT: No broadened claims permitted Quantum v. Rodime...

Page 1095 Rodime requested reexamination and, during the ensuing proceedings, amended the track density limitation from “at least 600” to “at least approximately 600” tpi

35 U.S.C. § 305 states, in relevant part, that “[n]o proposed amended or new claim enlarging the scope of a claim of the patent will be permitted in a reexamination proceeding.”...

The term “at least approximately 600 tpi” therefore defines an open-ended range starting slightly below 600. Since the amended limitation includes subject matter not covered by the original claims, i.e. track densities below 600 tpi, we conclude that Rodime expanded the scope of their claims during reexamination in violation of 35 U.S.C. § 305.

Inter partes reexam Rationale Complaints Reform?

Patent Quality Control ex parte inexpensive inter partes Administrative Patent Revocation? expensive Prosecution District Court Federal Circuit Litigation inter partes moderately inexpensive low quality high quality good quality

Trends and issues in reexams Stay during litigation “Special dispatch” problems Beefed up inter partes proceeding/more use of proceedings?

Trends in reexam requests 2005: 59 inter partes reexams 524 Ex parte reexams instituted 2008: 168 inter partes 680 Ex parte reexams instituted

Stays pending reexam Extremely district- and even judge- dependent ED Texas: 20% grant rate for stays SD Cal, ND Ill: 85%, 65% in ND Cal -- Patently-O 11/1/2009

Zurko Fed Cir traditionally applied the “clearly erroneous” standard of review to PTO findings of fact Challenged in this case

Standards of review Clearly erroneous is stricter standard, allows more reversals by court, compared to “substantial evidence” standard Traditionally applied by CCPA, and then Fed Cir

At 1056 But the difference is a subtle one—so fine that (apart from the present case) we have failed to uncover a single instance in which a reviewing court conceded that use of one standard rather than the other would in fact have produced a different outcome.

APA Section 706 Section 706, originally enacted in 1946, sets forth standards that govern the “Scope” of court “review” of, e.g., agency factfinding (what we shall call court/agency review). It says that a“reviewing court shall—... “(2) hold unlawful and set aside agency... findings... found to be— “(A) arbitrary, capricious, [or] an abuse of discretion, or “(E) unsupported by substantial evidence in a case subject to sections 556 and 557 of this title or otherwise reviewed on the record of an agency hearing provided by statute;...

Arti Rai

Pre-Zurko (“clearly erroneous” standard) Post-Gartside (“substantial evidence” standard) Affirmances5768 Reversals/remands2613 Percentage affirmance 68.7%83.9% From Arti Rai, Duke Law School